Picture of Hologic logo

HOLX — Hologic News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapNeutral

Hologic Q4 revenue beats expectations on higher core U.S. molecular diagnostics sales

Overview

Women's health company Hologic's fiscal Q4 rev grows 6.2% yr/yr, beating analyst expectations

Non-GAAP EPS for fiscal Q4 beats consensus, increasing 11.9%

Company to be acquired by Blackstone and TPG for up to $79 per share

Outlook

Company is not providing guidance due to acquisition by Blackstone and TPG

Result Drivers

DIAGNOSTICS GROWTH - Higher core U.S. molecular diagnostics sales drove diagnostics revenue growth, offset by lower COVID-19 assay sales and reduced sales in China

BREAST HEALTH - Growth driven by strong interventional product sales and improved U.S. sales execution

SURGICAL REVENUE - Increased sales of MyoSure and Fluent, and contributions from Gynesonics acquisition boosted surgical revenue

Key Details

MetricBeat/MissActualConsensus Estimate
Q4 RevenueBeat$1.04 bln$1.03 bln (13 Analysts)
Q4 Adjusted EPSBeat$1.13$1.10 (14 Analysts)
Q4 EPS$0.83
Q4 Adjusted Net IncomeBeat$254.70 mln$246.10 mln (12 Analysts)
Q4 Adjusted EBITDABeat$347 mln$346.05 mln (11 Analysts)
Q4 Adjusted Gross Margin60.90%
Analyst Coverage The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 15 "hold" and no "sell" or "strong sell" The average consensus recommendation for the advanced medical equipment & technology peer group is "buy." Wall Street's median 12-month price target for Hologic Inc is $75.50, about 2.1% above its October 31 closing price of $73.91 The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago Press Release: ID:nBw81t6qGa For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Hologic

See all news